Novel Complication of Nusinersen Treatment: Hyponatremia

Article Sidebar

PDF HTML
Submitted: October 3, 2018
Published: Oct 15, 2018
DOI: 10.29328/journal.jcicm.1001014
Crossref
Scopus
Google Scholar
Europe PMC

Main Article Content

Yasemin Coban
Sutcu Imam University, Medical Faculty, Department of Pediatrics, Division of Pediatric Intensive Care, Kahramanmaraş, Turkey

Abstract

There are variations in therapeutic regimens of different liver diseases. The accurate diagnosis ensNusinersen treatment is a novel therapy for spinal muscular atrophy (SMA) type 1; consequently, the adverse reactions of the therapy, have not been well known, yet. The present study is a case report that declares a hyponatremia development after the nursinersen therapy. Since the therapy is quite new one and has limited practice, we hope that this rare complication will contribute to the scientific literature.

Article Details

Coban, Y. (2018). Novel Complication of Nusinersen Treatment: Hyponatremia. Journal of Clinical Intensive Care and Medicine, 3(1), 020–022. https://doi.org/10.29328/journal.jcicm.1001014
Case Reports

Copyright (c) 2018 Coban Y.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Biogen Inc. SPINRAZA (nusinersen) injection, for intrathecal use: US prescribing information. 2016; Ref.: https://goo.gl/DjKjoi

Spinraza (nusinersen) Prescribing Information. Cambridge, MA: Biogen, 2017;

Farrar MA, Park SB, Vucic S, Carey KA, Turner BJ, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017; 81: 355–368. Ref.: https://goo.gl/rewjnT

Claborn MK, Stevens DL, Walker CK, Gildon B. Nusinersen in the Treatment of Spinal Muscular Atrophy. Methods Mol Biol. 2018; 1828: 69-76. Ref.: https://goo.gl/esiVFr

Ottesen EW. ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy. Transl Neurosci. 2017; 8: 1–6. Ref.: https://goo.gl/thWsps

Hoy SM. Nusinersen: first global approval. Drugs2017; 77: 473-479. Ref.: https://goo.gl/kZD3Cu

Safety Team Leader Review. NDA 209531. Spinraza (nusinersen). Benefit-Risk Summary and Assessment. Center for Drug Evaluatıon And Research. Reference ID: 4028770.

Jones DP. Syndrome of Inappropriate Secretion of Antidiuretic Hormone and Hyponatremia. Pediatr Rev 2018; 39: 27-35. Ref.: https://goo.gl/VPgG1i